"We share Discovery's passion for science and believe that combining our expertise in cell-based assays and drug screening with Discovery's broad multi-omics capabilities will enable us to provide a.…
Aug
25
2022
Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their.…
Aug
18
2022
Apr
25
2022
The ReachBio team is delighted to be returning to the Annual Meeting for The American Association of Immunologists next month in Portland, Oregon. Our CSO, Dr. Emer Clarke, will be presenting a.…
Mar
20
2020
Oct
10
2019
ReachBio is please to be participating in the 10th annual World ADC San Diego conference as a select exhibitor. ReachBio is the only CRO providing toxicity assays that will be exhibiting at this.…
Aug
27
2019
An article referencing ReachBio's new drug screening platform to discover therapeutic compounds that trigger the production of fetal hemoglobin (HbF) to treat sickle cell disease (SCD) and other.…
Aug
13
2019
SEATTLE, August 13, 2019 -- ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering a drug screening platform to.…
Jul
22
2019
SEATTLE, July 9, 2019 -- ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering off-target toxicity and linker.…
Apr
25
2019
Once again, ReachBio is excited to announce our continued sponsorship for the annual Applied Pharmaceutical Toxicology (APT) Conference in South San Francisco, California. This year's event will.…
